Financial reports
10-Q
2024 Q2
Quarterly report
7 Aug 24
10-Q
2024 Q1
Quarterly report
8 May 24
ARS
2023 FY
Annual report to shareholders
4 Apr 24
10-K
2023 FY
Annual report
19 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
4 Apr 23
10-K
2022 FY
Annual report
28 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
Current reports
8-K
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
7 Aug 24
8-K
DiaMedica Therapeutics Announces $11.8 Million
26 Jun 24
8-K
Regulation FD Disclosure
26 Jun 24
8-K
Departure of Directors or Certain Officers
23 May 24
8-K
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
8 May 24
8-K
Departure of Directors or Certain Officers
10 Apr 24
8-K
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
19 Mar 24
8-K
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
13 Nov 23
8-K
Departure of Directors or Certain Officers
5 Sep 23
8-K
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
14 Aug 23
Registration and prospectus
424B3
Prospectus supplement
18 Jul 24
S-3
Shelf registration
10 Jul 24
D
$11.80 mm in equity, sold $11.80 mm, 10 investors
2 Jul 24
S-8
Registration of securities for employees
24 May 24
S-3
Shelf registration
21 Mar 24
424B3
Prospectus supplement
10 Jul 23
S-3
Shelf registration
30 Jun 23
D
$37.54 mm in equity, sold $37.54 mm, 34 investors
27 Jun 23
D
$750.00 k in equity, sold $750.00 k, 1 investor
18 Apr 23
S-8
Registration of securities for employees
11 Aug 22
Proxies
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
DEFA14A
Additional proxy soliciting materials
4 Apr 23
DEF 14A
Definitive proxy
4 Apr 23
PRE 14A
Preliminary proxy
17 Mar 23
DEFA14A
Additional proxy soliciting materials
5 Apr 22
DEF 14A
Definitive proxy
5 Apr 22
DEFA14A
Additional proxy soliciting materials
3 Jun 21
DEF 14A
Definitive proxy
3 Jun 21
DEFA14A
Additional proxy soliciting materials
20 Apr 20
Other
EFFECT
Notice of effectiveness
19 Jul 24
EFFECT
Notice of effectiveness
10 Apr 24
EFFECT
Notice of effectiveness
10 Jul 23
CORRESP
Correspondence with SEC
5 Jul 23
UPLOAD
Letter from SEC
5 Jul 23
CT ORDER
Confidential treatment order
22 Dec 21
EFFECT
Notice of effectiveness
15 Oct 21
UPLOAD
Letter from SEC
12 Oct 21
CORRESP
Correspondence with SEC
12 Oct 21
EFFECT
Notice of effectiveness
5 May 21
Ownership
SC 13G
DIALECTIC CAPITAL MANAGEMENT, LP
8 Jul 24
144
Notice of proposed sale of securities
2 Jul 24
4
AB TomEnterprise
1 Jul 24
4
AB TRILL
1 Jul 24
4
David J. Wambeke
3 Jun 24
4
Scott Kellen
3 Jun 24
4
Dominic R Cundari
3 Jun 24
4
Dietrich John Pauls
3 Jun 24
4
Charles Pauling Semba
3 Jun 24
4
Richard D. Pilnik
3 Jun 24